Blockade of CD159a with targeted monoclonal antibodies has been shown to augment anti-tumor immunity as well as response to cancer vaccines and blocking CD159a may be a strategy worth exploring in patients with MM as well [48, 49]. Here, KLRC1 is linked to neoplasm.